FDA Approves Hugel America’s Letybo to Treat Moderate-to-Severe Frown Lines in Adults

Letybo (letibotulinumtoxinA-wlbg) is expected to launch in in the United States toward the second half of the year for moderate-to-severe frown (glabellar) lines in adults.

Source link
#FDA #Approves #Hugel #Americas #Letybo #Treat #ModeratetoSevere #Frown #Lines #Adults